{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:08:28Z","timestamp":1787317708605,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Septic shock typically requires the administration of vasopressors. Adrenergic agents remain the first choice, namely norepinephrine. However, their use to counteract life-threatening hypotension comes with potential adverse effects, so that non-adrenergic vasopressors may also be considered. The use of agents that act through different mechanisms may also provide an advantage. Nitric oxide (NO) is the main driver of the vasodilation that leads to hypotension in septic shock, so several agents have been tested to counteract its effects. The use of non-selective NO synthase inhibitors has been of questionable benefit. Methylene blue, an inhibitor of soluble guanylate cyclase, an important enzyme involved in the NO signaling pathway in the vascular smooth muscle cell, has also been proposed. However, more than 25\u00a0years since the first clinical evaluation of MB administration in septic shock, the safety and benefits of its use are still not fully established, and it should not be used routinely in clinical practice until further evidence of its efficacy is available.<\/jats:p>","DOI":"10.1186\/s13054-024-04839-w","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T07:02:26Z","timestamp":1708066946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Administration of methylene blue in septic shock: pros and cons"],"prefix":"10.1186","volume":"28","author":[{"given":"Julian","family":"Arias-Ortiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"4839_CR1","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1007\/s00134-020-06151-x","volume":"46","author":"C Fleischmann-Struzek","year":"2020","unstructured":"Fleischmann-Struzek C, Mellhammar L, Rose N, Cassini A, Rudd KE, Schlattmann P, et al. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intensive Care Med. 2020;46:1552\u201362.","journal-title":"Intensive Care Med"},{"key":"4839_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s13054-020-02950-2","volume":"24","author":"M Bauer","year":"2020","unstructured":"Bauer M, Gerlach H, Vogelmann T, Preissing F, Stiefel J, Adam D. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019- results from a systematic review and meta-analysis. Crit Care. 2020;24:239.","journal-title":"Crit Care"},{"key":"4839_CR3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13054-019-2478-6","volume":"23","author":"JL Vincent","year":"2019","unstructured":"Vincent JL, Jones G, David S, Olariu E, Cadwell KK. Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Crit Care. 2019;23:196.","journal-title":"Crit Care"},{"key":"4839_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/AIA.0000000000000226","volume":"57","author":"J Arias","year":"2019","unstructured":"Arias J, Levy B, De Backer D. Fifty years of management of vasodilatory shock. Int Anesthesiol Clin. 2019;57:31\u201347.","journal-title":"Int Anesthesiol Clin"},{"key":"4839_CR5","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s00134-020-06025-2","volume":"46","author":"RF Stolk","year":"2020","unstructured":"Stolk RF, Kox M, Pickkers P. Noradrenaline drives immunosuppression in sepsis: clinical consequences. Intensive Care Med. 2020;46:1246\u20138.","journal-title":"Intensive Care Med"},{"key":"4839_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-3-319-73506-1_9","volume-title":"Handbook of Sepsis","author":"J Arias-Ortiz","year":"2018","unstructured":"Arias-Ortiz J, De Backer D. Vasopressors in sepsis. In: Wiersinga W, Seymour C, editors. Handbook of Sepsis. Cham: Springer; 2018. p. 127\u201338."},{"key":"4839_CR7","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1097\/CCM.0000000000000436","volume":"42","author":"P Asfar","year":"2014","unstructured":"Asfar P, Chawla L, Lerolle N, Radermacher P. Angiotensin-II: more than just another vasoconstrictor to treat septic shock-induced hypotension? Crit Care Med. 2014;42:1961\u20133.","journal-title":"Crit Care Med"},{"key":"4839_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/SHK.0000000000000426","volume":"44","author":"C Martin","year":"2015","unstructured":"Martin C, Medam S, Antonini F, Alingrin J, Haddam M, Hammad E, et al. Norepinephrine: not too much, too long. Shock. 2015;44:305\u20139.","journal-title":"Shock"},{"key":"4839_CR9","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.2174\/138161206778343000","volume":"12","author":"BG Harbrecht","year":"2006","unstructured":"Harbrecht BG. Therapeutic use of nitric oxide scavengers in shock and sepsis. Curr Pharm Des. 2006;12:3543\u20139.","journal-title":"Curr Pharm Des"},{"key":"4839_CR10","doi-asserted-by":"publisher","first-page":"29541","DOI":"10.1074\/jbc.270.49.29541","volume":"270","author":"J Spink","year":"1995","unstructured":"Spink J, Cohen J, Evans TJ. The cytokine responsive vascular smooth muscle cell enhancer of inducible nitric oxide synthase. Activation by nuclear factor-kappa B. J Biol Chem. 1995;270:29541\u20137.","journal-title":"J Biol Chem"},{"key":"4839_CR11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMra002709","volume":"345","author":"DW Landry","year":"2001","unstructured":"Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med. 2001;345:588\u201395.","journal-title":"N Engl J Med"},{"key":"4839_CR12","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00134-010-2045-8","volume":"36","author":"B Levy","year":"2010","unstructured":"Levy B, Collin S, Sennoun N, Ducrocq N, Kimmoun A, Asfar P, et al. Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Med. 2010;36:2019\u201329.","journal-title":"Intensive Care Med"},{"key":"4839_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40635-019-0274-x","volume":"7","author":"S Lambden","year":"2019","unstructured":"Lambden S. Bench to bedside review: therapeutic modulation of nitric oxide in sepsis-an update. Intensive Care Med Exp. 2019;7:64.","journal-title":"Intensive Care Med Exp"},{"key":"4839_CR14","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.1073\/pnas.1804932115","volume":"115","author":"R Radi","year":"2018","unstructured":"Radi R. Oxygen radicals, nitric oxide, and peroxynitrite: Redox pathways in molecular medicine. Proc Natl Acad Sci U S A. 2018;115:5839\u201348.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4839_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-023-04835-8","author":"SK Prajapat","year":"2023","unstructured":"Prajapat SK, Maharana KC, Singh S. Mitochondrial dysfunction in the pathogenesis of endothelial dysfunction. Mol Cell Biochem. 2023. https:\/\/doi.org\/10.1007\/s11010-023-04835-8.","journal-title":"Mol Cell Biochem"},{"key":"4839_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/BF01706481","volume":"18","author":"F Schneider","year":"1992","unstructured":"Schneider F, Lutun P, Hasselmann M, Stoclet JC, Tempe JD. Methylene blue increases systemic vascular resistance in human septic shock. Preliminary observations Intensive Care Med. 1992;18:309\u201311.","journal-title":"Preliminary observations Intensive Care Med"},{"key":"4839_CR17","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/BF01700666","volume":"21","author":"B Gachot","year":"1995","unstructured":"Gachot B, Bedos JP, Veber B, Wolff M, Regnier B. Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Med. 1995;21:1027\u201331.","journal-title":"Intensive Care Med"},{"key":"4839_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/B978-0-12-804273-1.00022-3","volume-title":"Nitric Oxide","author":"PA Loughran","year":"2017","unstructured":"Loughran PA, Lei Z, Xu L, Deng M, Billiar TR. Nitric oxide in sepsis and hemorrhagic shock: beneficial or detrimental? In: Ignarro LJ, Freeman BA, editors. Nitric Oxide. 3rd ed. Cambridge: Academic Press; 2017. p. 289\u2013300.","edition":"3"},{"key":"4839_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/01.CCM.0000105581.01815.C6","volume":"32","author":"A Lopez","year":"2004","unstructured":"Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32:21\u201330.","journal-title":"Crit Care Med"},{"key":"4839_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s13181-013-0298-7","volume":"9","author":"DH Jang","year":"2013","unstructured":"Jang DH, Nelson LS, Hoffman RS. Methylene blue for distributive shock: a potential new use of an old antidote. J Med Toxicol. 2013;9:242\u20139.","journal-title":"J Med Toxicol"},{"key":"4839_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13054-022-04075-0","volume":"26","author":"J Singh","year":"2022","unstructured":"Singh J, Lee Y, Kellum JA. A new perspective on NO pathway in sepsis and ADMA lowering as a potential therapeutic approach. Crit Care. 2022;26:246.","journal-title":"Crit Care"},{"key":"4839_CR22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1213\/ANE.0000000000001045","volume":"122","author":"L Hosseinian","year":"2016","unstructured":"Hosseinian L, Weiner M, Levin MA, Fischer GW. Methylene blue: Magic bullet for vasoplegia? Anesth Analg. 2016;122:194\u2013201.","journal-title":"Anesth Analg"},{"key":"4839_CR23","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1007\/s12325-020-01422-x","volume":"37","author":"F Puntillo","year":"2020","unstructured":"Puntillo F, Giglio M, Pasqualucci A, Brienza N, Paladini A, Varrassi G. Vasopressor-sparing action of methylene blue in severe sepsis and shock: a narrative review. Adv Ther. 2020;37:3692\u2013706.","journal-title":"Adv Ther"},{"key":"4839_CR24","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/17512433.2022.2110067","volume":"15","author":"TE Albertson","year":"2022","unstructured":"Albertson TE, Chenoweth JA, Lewis JC, Pugashetti JV, Sandrock CE, Morrissey BM. The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock. Expert Rev Clin Pharmacol. 2022;15:959\u201376.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"4839_CR25","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/00003246-199502000-00010","volume":"23","author":"JC Preiser","year":"1995","unstructured":"Preiser JC, Lejeune P, Roman A, Carlier E, De Backer D, Leeman M, et al. Methylene blue administration in septic shock: a clinical trial. Crit Care Med. 1995;23:259\u201364.","journal-title":"Crit Care Med"},{"key":"4839_CR26","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1097\/00003246-200110000-00002","volume":"29","author":"MY Kirov","year":"2001","unstructured":"Kirov MY, Evgenov OV, Evgenov NV, Egorina EM, Sovershaev MA, Sveinbjornsson B, et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med. 2001;29:1860\u20137.","journal-title":"Crit Care Med"},{"key":"4839_CR27","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1177\/0310057X0203000606","volume":"30","author":"D Memis","year":"2002","unstructured":"Memis D, Karamanlioglu B, Yuksel M, Gemlik I, Pamukcu Z. The influence of methylene blue infusion on cytokine levels during severe sepsis. Anaesth Intensive Care. 2002;30:755\u201362.","journal-title":"Anaesth Intensive Care"},{"key":"4839_CR28","doi-asserted-by":"publisher","first-page":"1014276","DOI":"10.3389\/fmed.2022.1014276","volume":"9","author":"S Sari-Yavuz","year":"2022","unstructured":"Sari-Yavuz S, Heck-Swain KL, Keller M, Magunia H, Feng YS, Haeberle HA, et al. Methylene blue dosing strategies in critically ill adults with shock-A retrospective cohort study. Front Med (Lausanne). 2022;9:1014276.","journal-title":"Front Med (Lausanne)"},{"key":"4839_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13054-023-04397-7","volume":"27","author":"M Ibarra-Estrada","year":"2023","unstructured":"Ibarra-Estrada M, Kattan E, Aguilera-Gonzalez P, Sandoval-Plascencia L, Rico-Jauregui U, Gomez-Partida CA, et al. Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. Crit Care. 2023;27:110.","journal-title":"Crit Care"},{"key":"4839_CR30","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1592\/phco.30.7.702","volume":"30","author":"CA Paciullo","year":"2010","unstructured":"Paciullo CA, McMahon Horner D, Hatton KW, Flynn JD. Methylene blue for the treatment of septic shock. Pharmacotherapy. 2010;30:702\u201315.","journal-title":"Pharmacotherapy"},{"key":"4839_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.950596","volume":"9","author":"CC Zhao","year":"2022","unstructured":"Zhao CC, Zhai YJ, Hu ZJ, Huo Y, Li ZQ, Zhu GJ. Efficacy and safety of methylene blue in patients with vasodilatory shock: A systematic review and meta-analysis. Front Med (Lausanne). 2022;9: 950596.","journal-title":"Front Med (Lausanne)"},{"key":"4839_CR32","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1053\/j.jvca.2023.09.037","volume":"38","author":"A Pruna","year":"2024","unstructured":"Pruna A, Bonaccorso A, Belletti A, Turi S, Di Prima AL, D\u2019Amico F, et al. Methylene blue reduces mortality in critically ill and perioperative Patients: a meta-analysis of randomized trials. J Cardiothorac Vasc Anesth. 2024;38:268\u201374.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"4839_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-080065","volume":"14","author":"X Huang","year":"2024","unstructured":"Huang X, Yan W, Chen Z, Qian Y. Effect of methylene blue on outcomes in patients with distributive shock: a meta-analysis of randomised controlled trials. BMJ Open. 2024;14: e080065.","journal-title":"BMJ Open"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-024-04839-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-024-04839-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-024-04839-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T11:08:10Z","timestamp":1708340890000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-024-04839-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4839"],"URL":"https:\/\/doi.org\/10.1186\/s13054-024-04839-w","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"5 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JLV is editor-in-chief of Critical Care. He has no other conflicts of interest related to this manuscript JAO has no conflicts of interest related to this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}